2021
Strengthening the FDA’s Enforcement of ClinicalTrials.gov Reporting Requirements
Ramachandran R, Morten CJ, Ross JS. Strengthening the FDA’s Enforcement of ClinicalTrials.gov Reporting Requirements. JAMA 2021, 326: 2131-2132. PMID: 34766971, DOI: 10.1001/jama.2021.19773.Commentaries, Editorials and LettersMeSH KeywordsActivin Receptors, Type IIAntineoplastic AgentsAxitinibCarcinoma, Renal CellClinical Trials as TopicClinical Trials, Phase II as TopicDrug IndustryHumansImmunoglobulin Fc FragmentsKidney NeoplasmsLaw EnforcementMandatory ReportingNational Institutes of Health (U.S.)Recombinant Fusion ProteinsRegistriesUnited StatesUnited States Food and Drug Administration
2016
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCohort StudiesDatabases, FactualDiabetic RetinopathyDrug UtilizationFemaleHumansInsurance, HealthIntravitreal InjectionsMacular DegenerationMaleMedicare Part CMiddle AgedOphthalmologyPrivate SectorRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesUnited StatesVascular Endothelial Growth Factor AYoung AdultConceptsAge-related macular degenerationDiabetic retinal diseaseAnti-VEGF injectionsIntravitreal anti-VEGF injectionsRetinal vein occlusionAdministrative claims dataRetinal diseasesOphthalmic diseasesVein occlusionClaims dataUse of bevacizumabCurrent Procedural Terminology codesPatients 18 yearsRetrospective cohort studyMedicare Advantage patientsOptumLabs Data WarehouseDrug Administration approvalProcedural Terminology codesGrowth factor useRanibizumab useBevacizumab useAvailable medicationsCohort studyMedication useCommon medications